{"entity":{"id":"nct06110572","kind":"trial","name":"Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation","aka":["TESSERACT"],"tldr":"A phase 1/2 trial of carboplatin, atezolizumab and etoposide in lung cancer, run by Vanderbilt-Ingram Cancer Center, now recruiting.","summary":"Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation is a phase 1/2, interventional study registered as NCT06110572 by Vanderbilt-Ingram Cancer Center, with a registry enrolment figure of 18 participants, started 2024-04-24 and due to reach its primary completion in 2027-06-30. Interventions recorded: Carboplatin; Atezolizumab; Etoposide; Total Body Irradiation; Hypofractionated Radiation Therapy; Magnetic Resonance Imaging. Conditions listed: Extensive Stage Lung Small Cell Carcinoma; Stage IV Lung Cancer. Primary outcome: Rates of treatment-related adverse events; Progression-free survival. Lung eligibility wording from the registry: \"* Histologically documented or cytologically confirmed diagnosis of extensive stage small-celllung cancer with evaluable disease per RECIST v1\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT06110572","url":"https://clinicaltrials.gov/study/NCT06110572"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["extensive-stage-sclc"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","imrt-igrt","platinum","topoisomerase-inhibitors"],"targets":[],"drugs":["carboplatin","atezolizumab","etoposide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06110572","phase":"1/2","setting":"(TESSERACT): Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation (TBI)","sponsor":"Vanderbilt-Ingram Cancer Center","enrolled":18,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06110572/","neighbours":{"cancer":[{"id":"extensive-stage-sclc","kind":"cancer","name":"Extensive-stage small-cell lung cancer","route":"/cancers/extensive-stage-sclc/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"},{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"etoposide","kind":"drug","name":"Etoposide","route":"/drugs/etoposide/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}